Aminoazetidine,-pyrrolidine and -piperidine derivatives

A compound of the general formula (I):

• wherein
• R1 represents
• hydrogen,
• C1-8-alkyl, C3-8-alkenyl or C3-8-alkynyl,
• which may optionally be substituted with one or more halogen atoms,
• cyclobutyl, C3-7-cycloalkenyl, C4-8-bicycloalkyl, C3-7-cycloalkyl-C1-3-alkyl or C3-7-cycloalkenyl-C1-3-alkyl,
• which may optionally be substituted at any position with one or more halogen atoms,
• R2 represents C1-6-alkyl,
• f is 0, 1 or 2,
• X represents —(CH2)m—(Z)n—(CHZ)o—,
• m and o independently are 0, 1, 2, 3 or 4,
• n is 0 or 1,
• Z is —O—, —NH—, —N(CH3)—, —C(═O)—, —CH(OH)—, —CH(O—C1-6-alkyl)-, —C(═N—OH)—, —S—, —S(═O)—, —S═O)2—, —CH═CH— or —C═C—,
• Y is
• (a) aryl or heteroaryl, which may optionally be substituted with one or more substituents selected from
• halogen, nitro, cyano, hydroxy, C1-6-alkanoyl, C1-6-alkylthio, C1-6-alkylsulfonyl, C1-6-alkyl, C1-6-alkoxy, C3-8-cycloalkyl, trifluoromethyl, trifluoromethoxy, —NR3R4 and —O(C═O)NR3R4, or wherein two substituents in adjacent positions form a radical —O—(CH2)1-3—O—,
• wherein R3 and R4 independently are hydrogen, C1-6-alkyl, C3-8-cycloalkyl, C1-6-alkanoyl or aryl, or R3 and R4 together with the nitrogen atom to which they are attached form a 4 to 7 membered, saturated or unsaturated azetidinyl, pyrrolidinyl, piperidyl or azepanyl ring,
• wherein said heteroaryl is selected from the group consisting of furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, tetrazolyl, thiadiazinyl, indolyl, isoindolyl, benzofuryl, benzothienyl, indazolyl, benzimidazolyl, benzothiazolyl, benzoisothiazolyl, benzoxazolyl, benzisoxazolyl, purinyl, quinazolinyl, quinolizinyl, quinolinyl, isoquinolinyl, quinoxalinyl, napththyridinyl, pteridinyl, carbazolyl, azepinyl, diazepinyl, acridinyl and partially hydrogenated derivatives thereof
• aryl, aryloxy, aryl-C1-6-alkyl and aryl-C1-6-alkoxy, wherein the ring moieties optionally may be substituted with one or more substituents selected from
• halogen, nitro, cyano, hydroxy, C1-6-alkanoyl, C1-6-alkylthio, C1-6-alkylsulfonyl, C1-6-alkyl, C1-6-alkoxy, C3-8-cycloalkyl, trifluoromethyl, trifluoromethoxy, —NR5R6 and —O(C═O)NR5R6, or wherein two substituents in adjacent positions form a radical —O—(CH2)1-3—O—,
• wherein R5 and R6 independently are hydrogen, C1-6-alkyl, C3-8-cycloalkyl, C1-6-alkanoyl or aryl, or R5 and R6 together with the nitrogen atom to which they are attached form a 4 to 7 membered, saturated or unsaturated azetidinyl, pyrrolidinyl, piperidyl or azepanyl ring,
• (b) C3-8-cycloalkyl or C5-8-cycloalkenyl, which may optionally be substituted with one or more substituents selected from
• C1-6-alkyl, C1-6-alkoxy, C1-6-alkylthio, cyano, trifluoromethyl, trifluoromethoxy and halogen,
• aryl and aryloxy, wherein the ring moieties optionally may be substituted with one or more substituents selected from
• halogen, nitro, cyano, hydroxy, C1-6-alkanoyl, C1-6-alkylthio, C1-6-alkylsulfonyl, C1-6-alkyl, C1-6-alkoxy, C3-8-cycloalkyl, trifluoromethyl, trifluoromethoxy, —NR7R8 and —O(C═O)NR7R8, or wherein two substituents in adjacent positions form a radical —O—(CH2)1-3—O—,
• wherein R7 and R8 independently are hydrogen, C1-6-alkyl, C3-8-cycloalkyl, C1-6-alkanoyl or aryl, or R7 and R8 together with the nitrogen atom to which they are attached form a 4 to 7 membered, saturated or unsaturated azetidinyl, pyrrolidinyl, piperidyl or azepanyl ring,
• as well as any diastereomer or enantiomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof,
• with the proviso that,
• when m, n, and o are 0, R1 must not be ethyl, or methyl,
• and with the proviso that the compound must not be